Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus:a randomized controlled clinical trial  

作　　者：陈思 CHEN Si(Dept Endocrinol&Metab,Shanghai Jiaotong Univ Med Sch,Affil Sixth People's Hosp,Shanghai Diabet Clin Center,Shanghai Key Diabet Mellitus Lab,Shanghai Diabet Instit,Shanghai 200233)

机构地区：[1]Dept Endocrinol&Metab,Shanghai Jiaotong Univ Med Sch,Affil Sixth People's Hosp,Shanghai Diabet Clin Center,Shanghai Key Diabet Mellitus Lab,Shanghai Diabet Instit,Shanghai 200233

出　　处：《China Medical Abstracts(Internal Medicine)》2023年第4期210-210,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate and compare the efficacy and safety of ultra-rapid lispro insulin(URLi)and humalog lispro(HL)in the treatment of type 2 diabetes mellitus.Methods This was an international multicenter,doubleblind,randomized controlled study.From May 2019 to January 2021,a total of 481 patients with type 2 diabetes mellitus,who had been using insulin for at least 90 days and had poor glycemic control,were included.

关 键 词：MELLITUS RANDOMIZED DIABETES 

分 类 号：R587.1[医药卫生—内分泌]